Malignant Head and Neck Tumors in Children: A Retrospective Study
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 120
- 试验地点
- 1
- 主要终点
- Overall survival (OS)
研究概览
简要总结
The aim of the study is to identify demographic characteristics, various histopathologies, and site preferences for each disease entity of malignant head and neck tumors in pediatric oncology patients & treatment outcomes in these patients, according to experience at South Egypt Cancer Institute which is the largest referral site in Upper Egypt.
详细描述
Background:
Although head and neck masses represent a common entity in children, malignancy is uncommon. Only very limited data are available in the literature on the incidence of childhood cancer of the head and neck worldwide.
Data from the United States National Cancer Institute database suggest that the head and neck are involved in 12 % of all childhood malignancies. The most common pediatric head and neck malignancies include Non Hodgkin lymphomas, Hodgkin lymphomas, rhabdomyosarcomas, thyroid malignancies, nasopharyngeal carcinomas (NPCs), salivary gland malignancies, and neuroblastomas.
Patients & Methods:
A hospital-based study, involving Pediatric cancer patients, those diagnosed with malignant tumors of the head & neck, in the period from 2001 January till 2015 December, and received treatment at the pediatric oncology department, their medical records will be retrospectively reviewed for data collection.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- — 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients whose age less than 19 years.
- •Patients diagnosed with a primary malignant tumor of the head & neck.
排除标准
- •Patients whose age more than 18 years.
- •Patients diagnosed with a malignant disease primarily arising from the bone marrow.
- •Patients diagnosed with tumors of the central nervous system.
- •Patients diagnosed with retinoblastoma.
结局指标
主要结局
Overall survival (OS)
时间窗: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years
Time from the date of initiation of treatment until death from any cause
Event Free Survival (EFS)
时间窗: Participants will be retrospectively followed forward in time from the date of initiation of treatment till the primary completion date of the study, an expected average of 5 years
Time from the date of initiation of treatment until disease progression, or death for any reason.
次要结局
未报告次要终点
研究者
Ahmed Mohammed Morsy, MD
Lecturer, Pediatric Oncology Department
Assiut University